UBS reiterates Buy on Protagonist Therapeutics stock citing Mimrylo launch progress
UBS reiterated a Buy rating and $184 price target for Protagonist Therapeutics (PTGX), citing progress in Mimrylo's launch. The stock has risen 83.5% over the past year. UBS attended a medical conference and noted favorable adoption prospects among specialists. PTGX recently received FDA approval for Mimrylo and Icotyde, leading to multiple analyst upgrades.
How this was made
The 30-second read
Why it matters
Analyst upgrades and reaffirmed Buy rating suggest a positive price catalyst.
Market read
The FDA approval and analyst upgrades provide a modest bullish signal for PTGX.
What to watch
Manufacturing scale and competition from existing PV treatments could temper upside.
Background
Protagonist Therapeutics received FDA approval for Mimrylo (rusfertide) to treat polycythemia vera and analysts upgraded the stock.
Ticker impact
UBS reiterates Buy and $184 price target after FDA approval of Mimrylo, citing favorable adoption outlook.
likely upward pressure as market prices in higher target and adoption expectations
Multiple analysts raised price targets and reaffirmed Buy ratings following the regulatory clearance.
Market effects
Potential boost for biotech sector as FDA approval may signal pipeline strength.
US biotech stocks could see modest gains.
Limited to investors tracking FDA‑cleared therapies.
Counterpoint
The approval may not translate into sales if payer coverage is limited.
Key entities
- CompanyProtagonist Therapeutics
Biotech firm with FDA‑approved drug Mimrylo.
- AnalystUBS
Reiterated Buy rating and $184 price target.
